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Abstract
Background: Even the best cancer surgery is usually associated with minimal residual disease. Whether
these remaining malignant cells develop into clinical recurrence is at least partially determined by adequacy
of host defense, especially natural killer cell function. Anesthetics impair immune defenses to varying
degrees, but nitrous oxide appears to be especially problematic. We therefore tested the hypothesis that
colorectal-cancer recurrence risk is augmented by nitrous oxide administration during colorectal surgery.
Methods: We conducted a 4- to 8-year follow-up of 204 patients with colorectal cancer who were
randomly assigned to 65% nitrous oxide (n = 97) or nitrogen (n = 107), balanced with isoflurane and
remifentanil. The primary outcome was the time to cancer recurrence. Our primary analysis was a
multivariable Cox-proportional-hazards regression model that included relevant baseline variables. In
addition to treatment group, the model considered patient age, tumor grade, dissemination, adjacent
organ invasion, vessel invasion, and the number of nodes involved. The study had 80% power to detect a
56% or greater reduction in recurrence rates (i.e., hazard ratio of 0.44 or less) at the 0.05 significance level.
Results: After adjusting for significant baseline covariables, risk of recurrence did not differ significantly
for nitrous oxide and nitrogen, with a hazard ratio estimate (95% CI) of 1.10 (0.66, 1.83), P = 0.72. No
two-way interactions with the treatment were statistically significant.
Conclusion:  Colorectal-cancer recurrence risks were not greatly different in patients who were
randomly assigned to 65% nitrous oxide or nitrogen during surgery. Our results may not support avoiding
nitrous oxide use to prevent recurrence of colorectal cancer.
Implications Statement: The risk of colorectal cancer recurrence was similar in patients who were
randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.
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Background
Colon cancer is the third most common cause of cancer in
the United States. Surgery is the standard treatment for
colorectal cancer and is often curative. Nevertheless, can-
cer surgery is associated with release of tumor cells into
the systemic circulation [1], and it is likely that minimal
residual disease is present after even the best surgery.
Whether disseminated tumor cells are able to establish
metastases depends on several factors, including the effi-
cacy of host immune responses, in particular the function
of natural killer cells which are the primary defense
against malignancy [2,3].
Perioperative factors that impair host immunity are thus
likely to facilitate local recurrence or establishment of
metastatic tumor after cancer surgery [4]. For example,
metastasis formation in murine models is promoted by
anesthetic drugs, most of which are immunosuppressive
[5-7]. The extent to which various anesthetic drugs depress
natural killer cell and other immune functions related to
countering malignancy varies considerably [5,7-9].
Nitrous oxide has been given to more than a billion surgi-
cal patients and possibly remains the most commonly
used general anesthetic. Nonetheless, it is well established
that this inhaled anesthetic interacts with vitamin B12,
resulting in selective inactivation of methionine synthase
that is a key enzyme in methionine and folate metabo-
lism. Nitrous oxide thus impairs one-carbon and methyl-
group transfers which are critical for DNA, purine, and
thymidylate synthesis [10]. Impaired synthesis restricts
formation of new cells such as those of the hematopoietic
system [11-13]. Nitrous oxide also depresses neutrophil
chemotaxis [14] and reduces proliferation of human
peripheral blood mononuclear cells [14].
Among the cells impaired by nitrous oxide are the
immune cells that fight malignancy [11,15]. For example,
nitrous oxide not only augments metastases in murine
experimental models, but generates metastases in organs
that are usually resistant [5]. Thus lung metastases in a
mouse tumor model were twice as common when major
surgery was conducted with nitrous oxide than with
sodium thiopental, ketamine, or halothane.
Local or distant recurrence after cancer surgery is thus
likely to be determined in part by a body's ability to han-
dle minimal residual disease in the immediate periopera-
tive period. Most anesthetics impair defenses against
malignancy, especially natural killer cells, and nitrous
oxide may be worse than others. We therefore tested the
hypothesis that nitrous oxide administration during
colorectal cancer surgery enhances recurrence risk.
Methods
In a previously published study, we evaluated the effect of
nitrous oxide on the incidence of postoperative wound
infection after colectomy [16]. Our major conclusion was
that nitrous oxide does not increase the incidence of post-
operative wound infection after colon resection. The cur-
rent study evaluated cancer recurrence in those patients
whose original indication for surgery was colorectal
malignancy. Patients were enrolled between November
11, 1998, and November 3, 2002, and our follow up
extended until March 23, 2007; cancer recurrence was
thus evaluated over a 4- to 8-year period. The study was
not registered because patient enrollment preceded devel-
opment of major public trial registries.
Both the original and the current study were conducted
with the approval of the Institutional Review Boards of
the participating hospitals. Written informed consent was
obtained for the original study, i.e., nitrous oxide/postop-
erative wound infection, and then was waived for the cur-
rent study. Briefly, patients enrolled in the original study
were aged 18 to 80 years old. All had colon resections,
usually for cancer or inflammatory bowel disease. All
patients were given 35% inspired oxygen during surgery,
which was balanced by either 65% nitrous oxide or nitro-
gen that was randomly assigned. The remainder of the iso-
flurane and remifentanil anesthetic was standardized, as
was antibiotic prophylaxis. All patients were kept normo-
thermic because hypothermia triples infection risk [17].
Among the 418 patients enrolled in the initial study, 10
were excluded from analysis for various reasons. 206
patients in the nitrous oxide group and 202 patients in the
nitrogen group thus completed the trial. Among these, 97
given nitrous oxide and 107 given nitrogen had initial
colorectal cancer surgery and were available for this anal-
ysis (fig. 1).
Follow-up was conducted by investigators who were
blinded to the original assignment to nitrous oxide or
nitrogen. Cancer registries were reviewed, patients were
contacted, and their health status confirmed with their
oncologists and/or general practitioners. Family members
and government authorities were contacted as necessary
to determine patients' current addresses or confirm mor-
tality. Our primary outcome was local or metastatic recur-
rence of colon cancer.
Baseline factors that were evaluated included age, sex,
diagnoses, preoperative carcinoembryonic antigen (CEA),
neoadjuvant treatment, site of tumor, Dukes and TNM
classification, tumor grading, number of examined lymph
nodes, number of involved nodes, vessel and neural inva-
sion, dissemination, and whether patients had a history of
malignancies other than colorectal cancer. Using survivorBMC Anesthesiology 2009, 9:1 http://www.biomedcentral.com/1471-2253/9/1
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function estimates from the control group (nitrogen),
with 39/97 observed events in the nitrous-oxide group
and 38/107 observed events in the nitrogen group, we had
an 80% power to detect a hazard ratios less than 0.44 or
greater than 2.3 at the 0.05 significance level, if such haz-
ard ratios indeed existed. Since more subtle effects of
nitrous oxide are likely of clinical interest, our study
should be considered exploratory.
Data Analysis
Cancer-free survival time was defined as the time from
surgery to recurrence for those patients who experienced
recurrence, and the time from surgery to the earlier of the
follow-up date and the death date (if something other
than cancer caused the death) for those patients who were
censored (i.e., did not experience an observed recurrence
before being lost to follow-up). Patients who did not have
Trial profile after Fleischmann E, Lenhardt R, Kurz A et al 2005 Figure 1
Trial profile after Fleischmann E, Lenhardt R, Kurz A et al 2005.
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a recorded recurrence date but died of cancer were
recorded as having a recurrence date similar to the date of
death. Due to lack of follow-up information, one patient
was censored on the first postoperative day. Four others
were censored within the first 40 postoperative days. All
but one other patient had at least 270 days of follow up.
Univariable comparison of the randomized groups for
time to recurrence of cancer was performed visually using
Kaplan-Meier estimates of the survivor function and sta-
tistically using the log-rank test. Cox proportional hazards
regression was also used to assess the relationship
between baseline factors and recurrence.
A multivariable-Cox-proportional-hazards-regression
model including all baseline variables independently sig-
nificant at P < 0.25 (that is, significant at P <0.25 in the
presence of other covariables) in the model, was fit in
order to better balance the treatment groups and to
increase precision in the estimation of the effect of type of
gas on survival. Any factor showing some univariable rela-
tionship with the type of gas administered (as determined
by univariable tests with a significance criterion of P
<0.40) was considered building the model.
Statistical analysis was performed with SAS statistical soft-
ware, Cary, NC, and the R programming language,
Vienna, Austria.
Results
Demographic, morphometric, and perioperative charac-
teristics of the treatment groups, are presented in Table 1.
Though we did not expect any imbalance in these charac-
teristics between the two groups due to randomized allo-
cation of type of inhaled gas, patients in the nitrous-oxide
group had slightly higher preoperative CEA values
(median [quartiles] of 4.9 [1.7, 13]) than patients in the
nitrogen group (3.4 [1.9, 7.5]). Additionally, patients
given nitrous oxide had some combination of chemother-
apy and radiation more frequently (61%) than patients
given nitrogen (52%). Nonetheless, these differences were
not statistically significant (P = 0.70 and P = 0.30, respec-
Table 1: Baseline Characteristics for 204 Colorectal Cancer Patients.
Nitrous Oxide Nitrogen
Factor Level N = 97 N = 107 P-Value
Gender Female 40 (41) 39 (37) 0.48
Hospital AKH 87 (90) 94 (88) 0.68
SMZ-OST 10 (10) 13 (12)
Dukes classification A 17 (19) 16 (16) 0.96
B 27 (30) 31 (30)
C 33 (36) 38 (37)
D 14 (15) 17 (17)
Tumor Grade G1 3 (3) 5 (5) 0.68
G2 67 (74) 75 (72)
G3 19 (21) 24 (23)
G4 1 (1) 0 (0)
Site Ascending Colon 10 (11) 18 (17) 0.73
Sigmoid Colon 28 (30) 30 (28)
Rectal 45 (48) 44 (42)
Cecum 10 (11) 13 (12)
Multiple 1 (1) 1 (1)
Dissemination Yes 23 (24) 25 (24) 0.92
Invasion to Adjacent Organs Yes 31 (33) 28 (26) 0.33
Neural Invasion Yes 9 (10) 10 (9) 0.95
Vessel Invasion Yes 21 (23) 27 (26) 0.63
Treatment of Tumor besides surgery None 36 (39) 50 (48) 0.30
Chemotherapy 30 (32) 30 (29)
Radiation 15 (16) 9 (9)
Both 12 (13) 16 (15)
Age (Years) 61 ± 11 63 ± 11 0.41
Number of Nodes examined 16 [12, 21] 15 [12, 23] 0.97
Number of involved Nodes 0 [0, 4] 1 [0, 3] 0.88
Preoperative CEA 4.9 [1.7, 13.0] 3.5 [1.9, 7.5] 0.70
Recurrence-free survival (years) 3.9 [1.2, 5.4] 4.4 [1.1, 5.2] 0.89
AKH is the Vienna General Hospital; SMZ-OST is the Danube Hospital, also in Vienna, Austria. Statistics presented as number (%), means ± SDs, or 
medians [first-to-third quartile range]. P-values, respectively, are from Pearson's Chi-Squared Test, Student's T-Test, and Wilcoxon's Rank Sum 
Test.BMC Anesthesiology 2009, 9:1 http://www.biomedcentral.com/1471-2253/9/1
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tively). Time-weighted end-tidal isoflurane partial pres-
sure was slightly, but significantly, greater in patients
assigned to nitrogen: 0.64% vs. 0.56% (P < 0.001). The
fraction of patients transfused and the number of trans-
fused units were similar in each group; opioid use in the
first two postoperative hours was also similar.
Median [quartiles] follow-up time was 4.2 [1.2, 5.4] years.
During follow-up, 38% (N = 36) of the nitrous oxide and
37% (N = 40) of the nitrogen patients died. Independent
of the available covariables, use of nitrous oxide was asso-
ciated with an estimated 33% reduction (95% CI -63%,
+22%) in mortality rate (P = 0.19).
On univariable analysis, no difference was found between
the nitrous oxide and nitrogen groups on cancer recur-
rence rates. Specifically, the ratio (95% CI) of cancer recur-
rence risk (i.e., hazard ratio) at any given point in time
(nitrous oxide vs. nitrogen) was estimated at 1.14 (0.73,
1.79), P = 0.56. Kaplan-Meier survivor function estimates
are summarized in Figure 2 and Table 2. The relationship
between baseline factors and survival is given in Table 3;
as expected, many factors were predictive of survival at the
0.05 significance level.
After adjusting for significant baseline covariables (multi-
variable model, Table 4), risk of recurrence did not differ
significantly for nitrous oxide and nitrogen, with a hazard
ratio estimate (95% CI) of 1.10 (0.66, 1.83), P = 0.72. The
multivariate model included treatment group as well as
age, tumor grade, dissemination, adjacent organ invasion,
vessel invasion, and number of involved nodes. No two-
way interactions with the treatment were statistically sig-
nificant. A plot of log [-log(survival)] against log(time)
showed that the hazard ratio (or risk ratio) of recurrence
between the experimental groups did not change over
time, satisfying this important assumption of the Cox pro-
portional hazards model.
Discussion
Despite significant improvements in diagnosis, surgical
technique, and adjuvant therapies, cancer recurrence
remains the primary cause of death in patients presenting
with colonic malignancies. Cancer surgery, sometimes the
best hope for cure, is nearly always associated with mini-
mal residual disease [1], and competence of host defense,
especially natural killer cell function, appears to be a crit-
ical determinant of whether residual disease develops into
clinical recurrence [4,18].
Anesthetics impair immune function to various degrees
[5,13]; and at least in animals, anesthetic interventions
that impair natural killer cells augment metastatic risk
[5,7,8,19,20]. For example, recurrence is more common
with general than regional anesthesia in retrospective
analyses of 129 women with breast cancer [21] and 225
men with prostate cancer (unpublished data). Similar
benefits of avoiding general anesthesia has been observed
with melanoma surgery [22]. Perioperative blood transfu-
sion, which impairs natural killer cell function [23] and
promotes angiogenesis (which is necessary for metas-
tases) [24], may also increase recurrence risk after some
types of cancer surgery [25] – although this conclusion
remains controversial [26,27].
Nitrous oxide impairs numerous immune functions,
including those critical for fighting cancer [5,11,15]. Our
study has limited power resulting from its relatively small
sample size. Increases in recurrence risk to as much as
83% or decreases by as much as 34% cannot be excluded.
A larger, randomized, clinical trial would thus be helpful.
We nonetheless note that previous major studies evaluat-
ing the effect of anesthetic interventions on cancer-recur-
rence risk in humans were retrospective; ours differs in
being the first prospective randomized trial with blinded
outcome assessment which markedly strengthens our
conclusion.
In our study, postoperative analgesia was provided by
patient-controlled intravenous opioids. In the first two
postoperative hours, opioid use was similar in patients
assigned to either nitrous oxide or nitrogen. Unfortu-
nately, opioid use beyond the first two hours of recovery
was not recorded. While it is thus possible that this con-
founds our analysis, it seems unlikely that intraoperative
administration of nitrous oxide, an extremely short-acting
Table 2: Summary of Kaplan-Meier Survivor Density Function Estimates.
Nitrous Oxide N = 97 Nitrogen N = 107
Time Survival (95% CI) # Events # Censored* # Left Survival (95% CI) # Events # Censored* # Left
6 Months 89 (83, 96) 10 3 84 90 (85, 96) 10 3 94
1 Year 81 (73, 89) 18 4 75 82 (74, 89) 19 4 84
2 Years 70 (61, 79) 28 6 63 71 (62, 80) 30 5 72
3 Years 67 (57, 76) 31 10 56 68 (59, 77) 33 8 66
5 Years 60 (50, 71) 36 29 32 61 (51, 71) 38 37 32
Last Observation 49 (34, 64) 39 58 0 61 (51, 71) 38 69 0
* Lost to follow-up before observed recurrence.BMC Anesthesiology 2009, 9:1 http://www.biomedcentral.com/1471-2253/9/1
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drug, would alter opioid requirements beyond the initial
recovery period.
Our original randomized study comparing nitrous oxide
to nitrogen had as its major outcome surgical wound
infection [16], with bowel distention being a secondary
outcome [28]. The primary enrollment criterion for our
original study was thus colon resection; however, only
about half of our patients had surgery for cancer. The only
inclusion criteria for this study, surgery for colorectal can-
cer, was applied after randomization of patients. How-
ever, there was no reason to believe that the anesthetic
groups within this chosen subset of patients would not be
balanced on baseline characteristics. As might thus be
expected, the groups did not differ substantially in terms
of baseline risk. Furthermore, our multivariate analysis
compensated for present baseline differences.
Of the 77 observed recurrences (per our definition), eight
did not have a diagnosed recurrence; instead, their death
certificates listed colorectal cancer as the cause of death.
Though this assumption relies on the accuracy of death
certificate information, we believe it is justifiable to
assume they recurred.
The primary anesthetic in our original study was isoflu-
rane, which impairs natural killer cells [8] and other
immune functions [20,29]. Patients assigned to nitrous
oxide were given 0.56 ± 0.13% isoflurane and those
assigned to nitrogen were given 0.64 ± 0.14%. While these
concentrations differed significantly, the difference was
trivial and almost surely unimportant. A consequence of
the original study being designed and powered for infec-
tion is that we had limited power to detect an effect of
nitrous oxide on recurrence of colorectal cancer. Nonethe-
Table 3: Univariable Cox Regression Model Results.
Variable Category or Units N Hazard Ratio (95% C.I.) P-Value
Gas Nitrogen 107 1.0 0.56
Nitrous Oxide 97 1.14 (0.73, 1.79)
Age 10 Years 204 1.12 (0.91, 1.36) 0.29
Gender Male 125 1.0 0.29
Female 79 1.27 (0.81, 2.00)
Hospital AKH 181 1.0 0.07
SMZO 23 0.91 (0.45, 1.83)
Number of Nodes examined 1 Node 194 1.00 (0.90, 1.11) 0.98
Number of involved Nodes 1 Node 194 1.17 (1.12, 1.22) < 0.001
Tumor Grade G1 8 1.0 0.06
G2 142 1.35 (0.33, 5.58)
G3 43 2.60 (0.61, 11.1)
G4 1 --
Treatment of Tumor None 86 1.0 0.01
Chemotherapy 60 1.84 (1.08, 3.16)
Radiation 24 0.82 (0.33, 2.00)
Both 28 2.39 (1.27, 4.50)
Log2(Preoperative CEA) 1 (Doubling) 144 1.32 (1.21, 1.44) < 0.001
Site Ascending 28 1.0 0.052
Sigmoid 58 2.99 (1.24, 7.25)
Rectum 89 2.23 (0.94, 5.32)
Cecum 23 1.36 (0.41, 4.45)
Multiple Colon Cancer 2 --
Dukes Classification A 33 1.0 < 0.001
B 58 1.27 (0.38, 4.21)
C 71 5.23 (1.85, 14.7)
D 31 16.5 (5.72, 47.7)
Dissemination No 153 1.0 < 0.001
Yes 48 7.82 (4.89, 12.5)
Adjacent Organ Invasion No 142 1.0 < 0.001
Yes 59 2.28 (1.44, 3.61)
Neural Invasion No 180 1.0 < 0.001
Yes 19 3.26 (1.84, 5.77)
Vessel Invasion No 151 1.0 < 0.001
Yes 48 3.37 (2.11, 5.36)BMC Anesthesiology 2009, 9:1 http://www.biomedcentral.com/1471-2253/9/1
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Kaplan-Meier Estimates (and 95% Equal Precision Confidence Bands) of recurrence-free survival for 107 Colorectal Cancer  Patients Receiving Nitrogen Gas (solid confidence bands) and 97 Receiving Nitrous Oxide Gas (dotted confidence bands) Figure 2
Kaplan-Meier Estimates (and 95% Equal Precision Confidence Bands) of recurrence-free survival for 107 Color-
ectal Cancer Patients Receiving Nitrogen Gas (solid confidence bands) and 97 Receiving Nitrous Oxide Gas 
(dotted confidence bands). Multivariable P = 0.72.
Table 4: Final Multivariable Cox Regression Model Results.
Model Parameter Reference or Units Hazard Ratio (95% C.I.) P-Value
Nitrous Oxide Nitrogen 1.10 (0.66, 1.83) 0.72
Age 10 Years 1.16 (0.93, 1.44) 0.18
Tumor Grade 1 0.73 (0.43, 1.25) 0.25
Dissemination (Yes) No 5.6 (3.1, 10.2) < 0.001
Invasion into Adjacent Organs (Yes) No 0.60 (0.30, 1.23) 0.16
Invasion into Vessels (Yes) No 1.54 (0.87, 2.70) 0.14
# involved Nodes 1 Node 1.16 (1.09, 1.24) < 0.001*BMC Anesthesiology 2009, 9:1 http://www.biomedcentral.com/1471-2253/9/1
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less, our results suggest that if nitrous oxide promotes can-
cer recurrence, the relative risk is modest.
Conclusion
In summary, colon-cancer recurrence risk was similar in
patients randomly assigned to intraoperative nitrous
oxide or nitrogen. Our power was relatively low, thus leav-
ing the possibility that nitrous oxide reduces risk by as
much as 34% or increases it by as much as 83%. Nonethe-
less, our results do not support avoiding nitrous oxide use
to prevent recurrence of colorectal cancer.
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